MP5 Clozapine Prescribing and Monitoring Guideline
Target Audience
All CWP staff
Purpose
The purpose of this guidance is to set out the standards for clinicians, pharmacy service providers, nursing staff and other health care professionals involved in the prescribing, administration and monitoring of clozapine. It covers initiation of clozapine (inpatient and community setting) and continuation of monitoring following initiation.
Origin
Lead executive
Medical Director
Author and contact number
Deputy Chief Pharmacist - 01244 397494
Senior Clinical Pharmacist - 01244 397355
Medicines Safety Pharmacist - 01244 397494
Policy dates & history
Implementation Date
22 July 2017
Approval Meeting
Medicines Management Group
Appendices
- MP5z - Appendix 6 - Clozapine information for General Practitioners.dotx
- MP5z - Appendix 5 - Clozapine side effects screening checklist.dotx
- MP5z - Appendix 4a - Clozapine prescription and administration card for Community initiation.dotx
- MP5z - Appendix 4c - Physical monitoring during Community clozapine initiation – for display in clinic or team base.dotx
- MP5z - Appendix 2d - Physical health monitoring (baseline and during Inpatient dose titration).dotx
- MP5z - Appendix 2c - Inpatient Slow Clozapine Titration over 28 days for those sensitive to side effects.dotx
- MP5z - Appendix 2a - Inpatient Clozapine Starting Regime for Adults (titration to 300mg in 14 days).dotx
- MP5z - Appendix 2b - Inpatient Clozapine Starting Regime for the Over 65s (slower titration to 200mg day).dotx
- MP5 - Appendix 4b - Physical monitoring recording charts for Community clozapine initiation.dotx
- CWP Clozapine Titration NEWS2 Booklet.pdf
- Medicine Management